Hyperbaric oxygen therapy is being explored as a long COVID treatment. Here’s what the research shows
Hyperbaric oxygen therapy is being explored as a long COVID treatment. Here’s what the research shows Some clinics are touting pressurized oxygen chambers as a treatment for long COVID, but the evid…
Hyperbaric oxygen therapy is being explored as a long COVID treatment. Here’s what the research shows Some clinics are touting pressurized oxygen cha
Read Full Story at Scientific American →Why This Matters
The push to repurpose hyperbaric oxygen therapy (HBOT) for long COVID reflects a broader reckoning with the limitations of conventional medicine in addressing post-viral syndromes. As millions grapple with lingering symptoms, the potential of HBOT to bridge the gap between experimental treatments and mainstream care could redefine treatment paradigms for chronic post-infectious conditions.
Background Context
Originally developed in the mid-20th century for deep-sea divers and burn patients, HBOT has long been a niche therapy with sporadic FDA approvals for specific conditions. Its resurgence in the long COVID era stems from anecdotal reports of symptom relief paired with a desperate demand for solutions, despite a lack of large-scale, peer-reviewed validation.
What Happens Next
Expect intensified regulatory scrutiny as clinics expand HBOT offerings, along with pressure on insurers to cover the costly sessions. The next phase of research—particularly randomized controlled trials—will determine whether this therapy gains legitimacy or remains a speculative option, with potential spillover effects for other chronic illnesses.
Bigger Picture
The HBOT long COVID debate mirrors broader trends in medical innovation, where unproven therapies gain traction amid public demand before rigorous science catches up. It also underscores the fragmentation of chronic illness treatment, where patients often navigate a labyrinth of experimental options in search of relief.
